I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 16 studies | 18% ± 3% | |
| CD16-positive, CD56-dim natural killer cell, human | 8 studies | 20% ± 4% | |
| glutamatergic neuron | 6 studies | 39% ± 23% | |
| CD16-negative, CD56-bright natural killer cell, human | 5 studies | 22% ± 5% | |
| cardiac muscle cell | 5 studies | 39% ± 7% | |
| astrocyte | 5 studies | 22% ± 6% | |
| endothelial cell | 4 studies | 25% ± 7% | |
| CD8-positive, alpha-beta T cell | 4 studies | 17% ± 2% | |
| epithelial cell | 4 studies | 24% ± 1% | |
| GABAergic neuron | 4 studies | 35% ± 10% | |
| oligodendrocyte precursor cell | 4 studies | 23% ± 5% | |
| interneuron | 4 studies | 34% ± 19% | |
| oligodendrocyte | 4 studies | 20% ± 3% | |
| B cell | 3 studies | 17% ± 1% | |
| lymphocyte | 3 studies | 17% ± 1% | |
| transit amplifying cell | 3 studies | 26% ± 12% |
